Illumina appoints Everett Cunningham Chief Commercial Officer

Rhea-AI Summary

Illumina (NASDAQ: ILMN) has appointed Everett Cunningham as Chief Commercial Officer (CCO), effective June 10, 2024. Cunningham brings over 20 years of commercial leadership experience across healthcare tech, life sciences, and pharmaceuticals, having previously served as CCO at Exact Sciences. He has also held senior roles at Quest Diagnostics, GE Healthcare, and Pfizer. Cunningham will be responsible for managing and guiding Illumina's global commercial operations. He succeeds Bas Verhoef, who will continue as Head of Region for Europe. CEO Jacob Thaysen expressed optimism about Cunningham's potential to advance Illumina's mission in genomics.

Positive

• Everett Cunningham's appointment as CCO brings over 20 years of commercial leadership experience.
• Previous roles at Exact Sciences, Quest Diagnostics, GE Healthcare, and Pfizer indicate a solid track record in the industry.
• Known for driving operational excellence and delivering top-line results.
• Experience in expanding into new markets, which could be beneficial for Illumina's growth.
• Strong leadership skills, particularly in leading teams through transformational change.

Negative

• Transitioning leadership roles may lead to initial operational disruptions.
• Cunningham's relocation could result in a short-term adjustment period.

Cunningham previously served as CCO for Exact Sciences and brings more than 20 years of commercial leadership across healthcare tech, life sciences, and pharma 

SAN DIEGO, June 3, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the appointment of Everett Cunningham as Chief Commercial Officer (CCO), effective June 10.   

Cunningham will be responsible for building, guiding, and managing the company's global commercial organization. He brings extensive commercial experience across the healthcare tech, life sciences, and pharmaceutical industries. Most recently, Cunningham served as Chief Commercial Officer at Exact Sciences, where he oversaw the company's marketing, sales, and customer service functions. Prior to Exact Sciences, he held various senior leadership roles at Quest Diagnostics, GE Healthcare, and Pfizer, where he spent 21 years as a commercial leader.   

Cunningham has a demonstrated track record of success in driving operational excellence, delivering top-line results, and expanding into new markets. He is known as a strong leader who has effectively led teams through transformational change to better serve customers.   

"I am thrilled to welcome Everett to the Illumina leadership team as we work to deliver on Illumina's mission to improve human health by unlocking the power of the genome," said Jacob Thaysen, Illumina CEO. "He brings tremendous commercial leadership experience to the role, along with a passion for solving some of the world's most pressing healthcare challenges. I am looking forward to seeing all that he and our global commercial teams can do together, capitalizing on our leadership position in next generation sequencing, and delivering the products, services, and solutions that address customers' most pressing needs." 

Cunningham will be relocating to San Diego. He succeeds Bas Verhoef, interim CCO and Head of Region, Europe, since January 2024. Verhoef will continue as Head of Region for Europe beginning June 10.  

About Illumina 
Illumina is improving human health by unlocking the power of the genome. Our focus on innovation has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. To learn more, visit illumina.com and connect with us on X (Twitter), Facebook, LinkedIn, Instagram, TikTok, and YouTube. 

Contacts 

Investors: 
Salli Schwartz 
858-291-6421 
IR@illumina.com 

Media: 
Bonny Fowler 
740-641-5579 
PR@illumina.com 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/illumina-appoints-everett-cunningham-chief-commercial-officer-302161847.html

SOURCE Illumina, Inc.

FAQ

Who is the new Chief Commercial Officer of Illumina?

Everett Cunningham is the new Chief Commercial Officer of Illumina, effective June 10, 2024.

What experience does Everett Cunningham bring to his role as CCO at Illumina?

Everett Cunningham brings over 20 years of commercial leadership experience across healthcare tech, life sciences, and pharmaceuticals. He previously served as CCO at Exact Sciences.

When will Everett Cunningham start his role as CCO at Illumina?

Everett Cunningham will start his role as Chief Commercial Officer of Illumina on June 10, 2024.

What are Everett Cunningham's past roles before joining Illumina?

Before joining Illumina, Everett Cunningham held senior leadership roles at Exact Sciences, Quest Diagnostics, GE Healthcare, and Pfizer.

Who did Everett Cunningham succeed as CCO of Illumina?

Everett Cunningham succeeded Bas Verhoef, who was the interim CCO and will continue as Head of Region for Europe.